Related Experiment Video
Updated: Jun 10, 2026
05:51
A Streamlined and Standardized Procedure for Generating High-Titer, High-Quality Adeno-Associated Virus Vectors Utilizing a Cell Factory Platform
Published on: May 3, 2024
Progress and prospects: foamy virus vectors enter a new age
1Section of Infectious Diseases, Jefferiss Research Trust Laboratories, Imperial College London, London, UK.
Gene Therapy
|July 16, 2010
Summary
Foamy viruses, though not found in humans, show promise as gene therapy vectors due to their safety and efficiency. Their ability to correct genetic defects, like in dogs with leukocyte adhesion deficiency, supports clinical use.
Area of Science:
- Virology
- Gene Therapy
- Retroviruses
Background:
- Foamy viruses are distinct from human retroviruses like HIV and MLV.
- They are widespread in mammals but do not infect human populations.
- Human exposure to foamy viruses has not resulted in disease or onward transmission.
Purpose of the Study:
- To evaluate foamy viruses as potential gene therapy vectors.
- To highlight their unique biological properties for therapeutic applications.
Main Methods:
- Analysis of foamy virus biological characteristics, including host range and integration profile.
- Review of existing data on foamy virus vector applications in disease models.
Main Results:
- Foamy viruses exhibit broad host range and efficient transduction of progenitor cells.
- Their integration profile is less prone to causing insertional mutagenesis.
- Successful long-term reversal of leukocyte adhesion deficiency in dogs using foamy virus vector therapy.
Conclusions:
- Foamy viruses possess favorable characteristics for gene therapy vector development.
- Their safety profile and efficacy in preclinical models support further clinical investigation.
